Skip to main navigation
Skip to search
Skip to main content
Prinses Máxima Centrum Home
Nederlands
English
Search content at Prinses Máxima Centrum
Home
Profiles
Research Groups
Equipment
Research output
Prizes
Activities
Press/Media
Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy
A. M.M. Eggermont
, V. Chiarion-sileni
, J. J. Grob
, R. Dummer
, J. D. Wolchok
, H. Schmidt
, O. Hamid
, C. Robert
, P. A. Ascierto
, J. M. Richards
, C. Lebbé
, V. Ferraresi
, M. Smylie
, J. S. Weber
, M. Maio
, L. Bastholt
, L. Mortier
, L. Thomas
, S. Tahir
, A. Hauschild
J. C. Hassel, F. S. Hodi, C. Taitt, V. De Pril, G. De Schaetzen, S. Suciu, A. Testori
Show 7 more
Show less
Research output
:
Contribution to journal
›
Article
›
peer-review
1248
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
95% Confidence Interval
8%
Adjuvant Therapy
100%
Advanced Melanoma
8%
Adverse Events
8%
Checkpoint Inhibitors
8%
Confidence Interval
16%
Cutaneous Melanoma
8%
Distant Metastasis
8%
Distant Metastasis Free Survival
25%
Gross Total Resection
16%
Hazard Ratio
25%
High Risk
8%
Immune-related Adverse Events (IrAEs)
25%
Ipilimumab
100%
Overall Survival
25%
Phase 3 Trial
8%
Phase II Trial
8%
Placebo
25%
Placebo Groups
41%
Prolonged Survival
100%
Recurrence Rate
16%
Recurrence-free Survival
25%
Recurrent Disease
8%
Stage III Melanoma
100%
Toxic Effects
8%
Nursing and Health Professions
Accident Prevention
8%
Adjuvant Therapy
100%
Adverse Event
33%
Body Weight
8%
Confidence Interval
25%
Cutaneous Melanoma
8%
Distant Metastasis
8%
Distant Metastasis Free Survival
25%
Hazard Ratio
25%
Ipilimumab
100%
Melanoma
100%
Melanoma Skin Cancer
8%
Overall Survival
25%
Placebo
66%
Recurrence Free Survival
25%
Recurrent Disease
16%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
33%
Cutaneous Melanoma
8%
Distant Metastasis
8%
Distant Metastasis Free Survival
25%
Ipilimumab
100%
Melanoma
100%
Melanoma Skin Cancer
8%
Overall Survival
25%
Placebo
66%
Recurrence Free Survival
25%
Recurrent Disease
16%